BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30623045)

  • 1. Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome.
    Matzen SMH; Raaschou-Jensen KK; Kallenbach K
    Health Sci Rep; 2018 Nov; 1(11):e90. PubMed ID: 30623045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.
    Kárai B; Bedekovics J; Miltényi Z; Gergely L; Szerafin L; Ujfalusi A; Kappelmayer J; Hevessy Z
    Int J Lab Hematol; 2017 Dec; 39(6):577-584. PubMed ID: 28625017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Abnormality of immunophenotyping in patients with myelodysplastic syndrome].
    Xu J; Guo YX; Zhao H; Hui WH; Wan SG; Sun XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):894-7. PubMed ID: 19698224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome].
    Liu C; An WB; Zhang JL; Zhang RR; Sun CC; Chang LX; Liu TF; Zou Y; Wang HJ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Oct; 20(10):819-824. PubMed ID: 30369356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.
    Wells DA; Benesch M; Loken MR; Vallejo C; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2003 Jul; 102(1):394-403. PubMed ID: 12649150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes.
    Lai B; Chen Y; Li M; Ye G; Luo H; Zhong Y; Guo X
    Clin Lab; 2022 Sep; 68(9):. PubMed ID: 36125138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.
    Scott BL; Wells DA; Loken MR; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2008 Oct; 112(7):2681-6. PubMed ID: 18606877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 Jan; ():. PubMed ID: 24431028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.
    Oelschlaegel U; Oelschlaeger L; von Bonin M; Kramer M; Sockel K; Mohr B; Wagenfuehr L; Kroschinsky F; Bornhaeuser M; Platzbecker U
    Cytometry B Clin Cytom; 2023 Mar; 104(2):141-150. PubMed ID: 34390327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.
    Dhingra G; Dass J; Arya V; Gupta N; Saraf A; Langer S; Aggarwal S; Kotwal J; Bhargava M
    Indian J Med Res; 2020 Sep; 152(3):254-262. PubMed ID: 33107485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.
    Aanei CM; Picot T; Tavernier E; Guyotat D; Campos Catafal L
    Front Oncol; 2016; 6():161. PubMed ID: 27446807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
    Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
    Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
    Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
    Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of the lymphoid screening tube supplemented with CD34 for Ogata score calculation in patients with peripheral cytopenia.
    Muyldermans A; Florin L; Devos H; Cauwelier B; Emmerechts J
    Hematology; 2019 Dec; 24(1):166-172. PubMed ID: 30334700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic syndrome.
    Pembroke JS; Joseph JE; Smith SABC; Parker AJC; Jiang W; Sewell WA
    Int J Lab Hematol; 2022 Apr; 44(2):313-319. PubMed ID: 34841680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome].
    Lu D; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.